Pub. Date : 2022
PMID : 35221708
11 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Methods: A Dox-controlled system was utilized to induce the expression of the ASC transgene in HEK293 cells while simultaneously overexpressing NLRP3 and CASP1. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 2 | The applicability and effectiveness of the CASPorter cell line were tested by co-treatment with Dox and four known CASP1/NLRP3 inhibitors (MCC950, Glyburide, VX-765 and VRT-043198). | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 3 | Results: Dox treatment significantly induced ASC expression and increased levels of cleaved and catalytically active CASP1, co-IPs further demonstrated that CASP1 was pulled-down with NLRP3 in HEK293-iASC-NLRP3/CASP1 cells after induction of ASC by Dox treatment. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 4 | Results: Dox treatment significantly induced ASC expression and increased levels of cleaved and catalytically active CASP1, co-IPs further demonstrated that CASP1 was pulled-down with NLRP3 in HEK293-iASC-NLRP3/CASP1 cells after induction of ASC by Dox treatment. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 5 | Results: Dox treatment significantly induced ASC expression and increased levels of cleaved and catalytically active CASP1, co-IPs further demonstrated that CASP1 was pulled-down with NLRP3 in HEK293-iASC-NLRP3/CASP1 cells after induction of ASC by Dox treatment. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 6 | Results: Dox treatment significantly induced ASC expression and increased levels of cleaved and catalytically active CASP1, co-IPs further demonstrated that CASP1 was pulled-down with NLRP3 in HEK293-iASC-NLRP3/CASP1 cells after induction of ASC by Dox treatment. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 7 | In HEK293-iASC-NLRP3/CASP1-CASPorter cell system, cleavage of the CASP1 consensus site (YVAD) in the CASPorter protein after Dox treatment causing excitation/emission of green fluorescence and the 71% GFP+ cell population increase quantified by FC (78.1% vs 6.90%). | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 8 | Dox-induced activation of the NLRP3 inflammasome was dose-dependently inhibited by Dox co-treatment with four known CASP1/NLRP3 inhibitors. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 9 | Dox-induced activation of the NLRP3 inflammasome was dose-dependently inhibited by Dox co-treatment with four known CASP1/NLRP3 inhibitors. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 10 | Dox-induced activation of the NLRP3 inflammasome was dose-dependently inhibited by Dox co-treatment with four known CASP1/NLRP3 inhibitors. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |
| 11 | Dox-induced activation of the NLRP3 inflammasome was dose-dependently inhibited by Dox co-treatment with four known CASP1/NLRP3 inhibitors. | Doxorubicin | NLR family pyrin domain containing 3 | Homo sapiens |